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a  b  s  t  r  a  c  t
INTRODUCTION:  Small-cell  carcinoma  of  the esophagus  (SCCE)  is  a rare disease  with  aggressive  progres-
sion and  a poor  prognosis.  A standard  treatment  strategy  for  SCCE  is  yet  to be established.
PRESENTATION  OF  CASE:  A  40-year-old  woman  with  dysphagia  was  admitted  to  our hospital.  A clinical
diagnosis  of  SCCE  (T3N1N0  stage  IIIA) was  established.  She  was initially  treated  with  chemotherapy
using cisplatin  (CDDP)  and  irinotecan  (CPT-11).  After  two courses  of treatment,  the  primary  lesion  in  the
esophagus  was  not  detectable  by  esophageal  endoscopy.  Likewise,  swelling  of the right  recurrent  nerve
lymph  node  present  prior to treatment  could  not  be  detected.  The  chemotherapy  resulted  in a  complete
response.  One  month  after  the  conclusion  of chemotherapy,  radical  esophagectomy  with  three-ﬁeld
lymph  node  dissection  was  performed.  Histopathological  examination  of  the  excised  specimen  revealed
no residual  tumor  or lymph  node  metastasis.  The  patient  was  discharged  from  hospital  29 days  after
surgery  with  no complications.  The  patient  is  alive  and  has  remained  cancer-free  for  48 months  after  the
surgery.
DISCUSSION:  Systemic  chemotherapy  for  SCCE  in  combination  with  surgery  was  treated  after  surgery  in
most  reports.  Neoadjuvant  chemotherapy  is  advantageous  from  three  viewpoints,  namely  achievement  of
downstaging,  increasing  complete  resection  rates,  and a  better completion  of  treatment  compared  with
postoperative  chemotherapy.  Neoadjuvant  chemotherapy  following  esophagectomy  could  be  a  useful
treatment  option  for patients  with  limited  disease  (LD) of SCCE.
CONCLUSION:  We  report  a  case  of  SCCE  achieving  a pathologically  complete  response  with  neoadjuvant
chemotherapy  using  CDDP  and  CPT-11,  and  long-term  survival  followed  by  surgery.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Extrapulmonary small-cell carcinoma is a rare condition,
ccounting for 2–5% of all small-cell carcinomas [1]. The most
ommon extrapulmonary sites of small-cell carcinoma include the
sophagus, other gastrointestinal organs, genitourinary tract, head
nd neck area, and the breast [2]. Gastrointestinal small-cell car-
inomas, including small-cell carcinoma of the esophagus (SCCE),
ave a poor prognosis [3]. SCCE is a rare disease, accounting for
.94–1.6% of all esophageal cancers [4,5]. SCCE has a poor prognosis
ecause of its aggressive progression and widespread dissemina-
∗ Corresponding author. Fax: +81 19 651 7166.
E-mail address: yakiyama@iwate-med.ac.jp (Y. Akiyama).
ttp://dx.doi.org/10.1016/j.ijscr.2015.11.005
210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tion with a median survival time (MST) of 3.4–19 months, and the
5-year survival rate is 6.7–15.4% [6].
A standard treatment strategy for SCCE is yet to be established
because of its low incidence. Here, we report a case of SCCE achiev-
ing a pathologically complete response following chemotherapy
with cisplatin and irinotecan, and long-term survival following
surgery.
2. Presentation of case
A 40-year-old woman  with dysphagia was admitted to our hos-
pital. Esophagogastroscopy revealed an ulcerated mass in the upper
thoracic esophagus (Fig. 1a), and histopathological examination of
the biopsy showed primary small-cell carcinoma (Fig. 2). A bar-
ium esophagram revealed a 20-mm mass with central ulceration in
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Esophagogastroscopy and barium esophagography for small-cell carcinoma. (a) Esophagogastroscopy performed at admission revealed an ulcerated mass in the upper
thoracic esophagus. (b) Esophagogastroscopy after one course of preoperative chemotherapy with cisplatin and irinotecan revealed that the lesion had markedly ﬂattened.
(c)  Esophagogastroscopy after two  courses of preoperative chemotherapy with cisplatin and irinotecan failed to detect any remaining signs of the tumor. (d) A barium
esophagram generated upon admission revealed a 20-mm mass with central ulceration in the upper thoracic esophagus.
Fig. 2. Pathological examination of endoscopic biopsy specimens from the esophagus. (a) The tumor cells had small round or spindle-shaped nuclei, ill-deﬁned cell borders,
ﬁnely granular nuclear chromatin, and inconspicuous nucleoli (hematoxylin-eosin stain; 400× magniﬁcation). (b) The tumor cells stained positive for synaptophysin (200×
magniﬁcation). (c) The tumor cells stained positive for CD56 (200× magniﬁcation). (d) More than 80% of the nuclei were positive for Ki-67 (200× magniﬁcation).
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mhickening in the upper thoracic esophagus was  reduced. (c) After two courses of pr
e  detected. (d) The enlarged right recurrent nerve lymph node at admission. (e) A
ymph node was  reduced. (f) After two courses of preoperative chemotherapy, the 
he upper thoracic esophagus (Fig. 1d). Computed tomography (CT)
can revealed an esophageal-wall thickening (Fig. 3a) and enlarged
ight recurrent nerve lymph node (Fig. 3d). The patient was  diag-
osed with SCCE (T3N1N0, stage IIIA).
She was initially treated with chemotherapy using cisplatin
CDDP) and irinotecan (CPT-11). She received two courses of CDDP
80 mg/m2 on day 1) and CPT-11 (70 mg/m2 on days 1 and 15) with
ach cycle repeated every 4 weeks. Grade 1 headache (according to
he Common Terminology Criteria for Adverse Events Version 4.0)
as observed during each course, whereas grade 3/4 adverse effects
ere not observed. After one course of chemotherapy, esophageal
ndoscopy revealed that the primary lesion in the esophagus had
arkedly ﬂattened (Fig. 1b). Furthermore, after two  courses of
Fig. 4. Surgical specimen of the esophagus. Noative chemotherapy, the wall thickening in the upper thoracic esophagus could not
ne course of preoperative chemotherapy, the swelling of the right recurrent nerve
ng of the right recurrent nerve lymph node could not be detected.
treatment, the tumor could not be detected (Fig. 1c). A CT scan
revealed a reduction in the esophageal-wall thickening (Fig. 3c),
and the swelling of the right recurrent nerve lymph node (Fig. 3f)
was not detected.
One month after the conclusion of chemotherapy, radical
esophagectomy with three-ﬁeld lymph node dissection and gastric
tube reconstruction was  performed using a thoracoscopic approach
in the prone position, laparotomy, and bilateral cervical approaches
(Fig. 4). Posterior mediastinal route reconstruction was achieved
using a gastric tube. The surgical duration was 666 min, and blood
loss was 44 mL.  Histopathological examination of the resected
specimen failed to reveal any residual cancer, and the histologi-
cal efﬁcacy of the chemotherapy was grade 3—markedly effective,
 residual tumor tissue could be detected.
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ith no variable cancer cells observed (according to the Japanese
lassiﬁcation of Esophageal Cancer, 10th edition) [7]. No lymph
ode metastasis was observed, and there were no chemotherapy-
ssociated complications during or after the surgery. The patient
as discharged from the hospital 29 days after the surgery with
o complications and treated with adjuvant chemotherapy using
DDP and CPT-11 in one course 2 months after the surgery, with
 dose similar to that given prior to treatment. The patient is alive
nd has remained cancer-free for 48 months after the surgery.
. Discussion
Although surgery, chemotherapy, radiotherapy, and a combi-
ation of these modalities have been used for SCCE as well as for
ther common types of esophageal cancer, the optimum treat-
ent strategy for SCCE remains to be established. The National
omprehensive Cancer Network (NCCN) guidelines for small-cell
arcinoma of the lung (SCCL) are usually used as references to
etermine the management of extrapulmonary small-cell carci-
oma. According to the NCCN guidelines, the indication of surgical
esection for SCCL is limited to clinical stage I (T1-2, N0), because
atients with diseases which have progressed beyond T1-2, N0 do
ot beneﬁt from surgery. In patients with extrapulmonary small-
ell carcinoma, surgical resection is also performed in cases with
imited disease (LD). Zhu et al. reviewed 64 cases of SCCE and
eported that 37 out of 46 (80.4%) patients with LD underwent sur-
ical resection [5]. Shinohara et al. summarized 23 cases of SCCE,
hich achieved >5 years of survival, reported in the literature and
eported that surgery had been performed in 17 cases (73.9%) [6].
urthermore, clinical data reviewed by Brenner et al. showed that
urgery could effectively extend the survival time of LD patients
3]. Therefore, it appears that esophagectomy is the predominant
reatment modality for patients with LD of SCCE. However, because
CCE is considered a systemic disease with a high risk of distant
etastasis, multimodal therapy based on systemic chemotherapy
as been suggested for treating this disease [8]. It has been reported
hat the MST  of patients treated using a single method was signiﬁ-
antly shorter than those treated using multimodality approaches,
nd that systemic chemotherapy signiﬁcantly improved MST  for
atients with extensive disease (ED) compared with that of locore-
ional treatment alone [5]. Chen et al. demonstrated that operation
nd chemotherapy were independent prognostic factors for SCCE
n multivariate analysis and recommended surgical resection com-
ined with chemotherapy to treat patients with LD of SCCE [9]. It
ppears that our present case of SCCE is a good example of a patient
chieving long-term survival by surgical resection combined with
hemotherapy.
For systemic chemotherapy of SCCL, etoposide/cisplatine (EP)
10] or irinotecan/cisplatin (IP) regimens are frequently used [11].
lthough signiﬁcant differences were not observed in overall sur-
ival between IP and EP in two phase III studies in USA [12,13], it has
een demonstrated that IP signiﬁcantly improves progression-free
urvival and overall survival compared with EP in a randomized
hase III study of SCCL with ED in Japan [11]. Moreover, in Japan,
P is the standard therapy for SCCL with ED; therefore, we have
elected the IP regimen for our patients. In terms of extrapulmonary
mall-cell carcinoma, a randomized phase III study conducted by
he Japanese Clinical Oncology Group (JCOG) for advanced extra-
ulmonary neuroendocrine carcinoma comparing IP therapy with
P therapy is currently in progress.
Although systemic chemotherapy for SCCE in combination withurgery was treated after surgery in most reports, several studies
ave reported cases of preoperative treatment with chemother-
py for SCCE [14,15]. In addition, it has been reported that
reoperative chemotherapy improves survival time compared withPEN  ACCESS
rgery Case Reports 17 (2015) 121–125
postoperative chemotherapy for patients with resectable stage II/III
esophageal squamous cell carcinoma (JCOG 9907) [16]. Neoadju-
vant chemotherapy is advantageous from three viewpoints, namely
achievement of downstaging, increasing complete resection rates,
and a better completion of treatment compared with postoperative
chemotherapy [16]. In the present case, the patient was  treated
with IP for SCCE, in accordance with the concept of neoadjuvant
chemotherapy for stage II/III esophageal squamous cell carcinoma.
Considering the aggressive behavior and poor prognosis of SCCE, we
added postoperative adjuvant chemotherapy with IP. The patient
achieved complete response following two  courses of preoperative
IP. The rate of complete response and response rate of chemother-
apy with IP for SCCL were 2.6% and 84.4%, respectively [11]. Chin
et al. reported 12 cases of IP for SCCE, with 2 out of 12 (16.6%)
patients with IP achieving complete response [17]. Neoadjuvant
chemotherapy following esophagectomy could be a useful treat-
ment option for patients with LD of SCCE.
4. Conclusions
Here, we reported on the successful treatment of SCCE with
preoperative chemotherapy using IP followed by surgery. Neoad-
juvant chemotherapy following esophagectomy could be a useful
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